Abstract: Relief valves are described herein. An example relief valve includes a valve body defining a fluid passageway between an inlet and an outlet. The valve body includes a first body portion having a first side with a first opening and a second with a second opening. The second opening forms the outlet of the fluid passageway. The first body portion is constructed of a first material. The valve body also includes a second body portion coupled to the first side of the first portion. The second body portion has a channel aligned with the first opening. The second body portion forms the inlet of the fluid passageway. The second body portion is constructed of a second material having a higher temperature rating than the first material. The relief valve also includes a nozzle and a flow control member moveable.

Abstract: Relief valves are described herein. An example relief valve includes a valve body defining a fluid passageway between an inlet and an outlet. The valve body includes a first body portion having a first side with a first opening and a second with a second opening. The second opening forms the outlet of the fluid passageway. The first body portion is constructed of a first material. The valve body also includes a second body portion coupled to the first side of the first portion. The second body portion has a channel aligned with the first opening. The second body portion forms the inlet of the fluid passageway. The second body portion is constructed of a second material having a higher temperature rating than the first material. The relief valve also includes a nozzle and a flow control member moveable.

Abstract: This disclosure relates to use of anti-IL-1? antibodies (e.g., canakinumab or gevokizumab) in a therapy treating, preventing, reducing, or alleviating one or more manifestations and complications in individuals suffering from sickle cell disease (including, e.g., homozygous HbS gene carriers, heterozygotes with sickle-beta-thalassemia with an SCD supporting combination of HbS gene and beta-tha1 gene, an individual with one sickle cell gene and one null allele, or an individual with hemoglobin sickle cell disease), optionally in combination with an additional therapeutic agent. Such manifestations and complications include, but are not limited to: pain, fatigue, hospitalization, poor sleep quality, work or school absences, narcotic use, acute or chronic blood transfusion therapy, acute chest syndrome, bone infarct, avascular necrosis, osteonecrosis, stroke, priapism, infarction of penis, a cardiovascular disorder, growth delay, stunted growth, low body mass index (BMI), low body weight, and organ damage.

Abstract: The present invention describes a method of reducing solid tumors in a subject having an adenoid cystic carcinoma comprising administering a therapeutically effective amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a method of treating a cancer in patient in need thereof by administering 4-amino-5 fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one, or a tautomer thereof, or a salt of any one of them, wherein the patient is a moderate hepatic impaired patient.

Abstract: The present invention relates to the method of treating hepatocellular cancer (HCC) with 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt or a tautomer thereof, or a hydrate or a solvate.

Abstract: The present invention describes methods for diagnosing, treating and determining the prognosis of breast cancer HR+ patient, the methods including detecting the amplification of one or more biomarkers comprising a FGFR ligand such as FGF3, FGF4, FGF19, and/or a FGFR, such as for example FGFR1 in a subject; determining an FGFR1 inhibitor for treating the subject based on the amplification of the one or more biomarkers in the subject; administering to the subject in need thereof the FGFR1 inhibitor and using the one or more biomarkers to indicate prognosis of the subject treated with the FGFR1 inhibitor.

Abstract: The use of 4-amino-5-fluoro-3[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt or a tautomer thereof, or a hydrate or a solvate for the manufacture of pharmaceutical compositions for use in the treatment of hepatocellular carcinoma or liver cancer.

Abstract: A pharmaceutical combination comprising 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one and at least one mTOR inhibitor and the pharmaceutical combination for use in treating or preventing a proliferative disease.